Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $44.00 by Analysts at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL) had its price target reduced by analysts at Needham & Company LLC from $46.00 to $44.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC‘s target price points to a potential upside of 77.20% from the company’s previous close.

Several other research analysts also recently issued reports on COLL. Leerink Partners assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target for the company. Zacks Research upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Oppenheimer initiated coverage on Collegium Pharmaceutical in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.43.

Collegium Pharmaceutical Stock Performance

Shares of COLL traded up $1.16 during mid-day trading on Thursday, hitting $24.83. 571,797 shares of the company’s stock were exchanged, compared to its average volume of 578,313. The firm has a market cap of $808.40 million, a price-to-earnings ratio of 19.96, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The stock’s 50-day simple moving average is $23.08 and its 200-day simple moving average is $33.01. Collegium Pharmaceutical has a 52 week low of $21.43 and a 52 week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.10. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The firm had revenue of $216.34 million during the quarter, compared to the consensus estimate of $216.03 million. During the same period in the prior year, the company posted $2.25 EPS. The company’s revenue was up 67.4% compared to the same quarter last year. On average, equities research analysts expect that Collegium Pharmaceutical will post 6.42 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Collegium Pharmaceutical during the second quarter worth about $196,972,000. Jupiter Topco LLC purchased a new stake in shares of Collegium Pharmaceutical in the second quarter worth $77,743,000. Janus Henderson Group PLC raised its holdings in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Bank of America Corp DE bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $9,882,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth $8,506,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.